Analysis
Foreign Investment in Australia: what you need to know
Registered Content
03 June 2021
David Holland
PartnerSydney
Email [email protected]hoganlovells.com
Phone +61 2 9093 3504
Fax +61 2 9093 3559
LanguagesEnglish
Practice groupCorporate & Finance
David Holland is a Partner in our Corporate and Finance team in Sydney. He is a leading M&A lawyer having acted on some of Australia's largest merger transactions in recent times. He advises major corporate organisations as well as government on proposed trade sales, purchases and initial public offerings.
His practice focuses on mergers and acquisitions and corporate and securities law, private company acquisitions, public company takeovers and mergers, Australian Securities Exchange rules and initial public offerings, capital raisings, securities issues and corporate governance and compliance.
Awards and recognitions
2016-2022
Corporate Law & Mergers and Acquisitions Law
Best Lawyers (Australia)
2019
Ranked as highly regarded lawyer for Capital Markets: Equity, and M&A
IFLR1000
2019
Noted in Band 3 for Capital Markets
Legal 500 Asia Pacific
Education and admissions
Education
LL.B., University of New South Wales, Australia, 1994
Bachelor of Commerce (BCom), University of New South Wales, Australia, 1992
Memberships
Law Society of New South Wales
Court admissions
Supreme Court of New South Wales
Representative experience
Advised Merck & Co on its acquisition of Viralytics for $502m by scheme of arrangement.*
Acted for Home Consortium on its acquisition of the Masters business from Woolworths.*
Advised Valeant Pharmaceuticals International on the sale of iNova Pharmaceuticals to a company jointly owned by Pacific Equity Partners and the Carlyle Group for US$930 million.*
Advised HT&E Limited on the acquisition of Adshel outdoor advertising and APN radio businesses, and associated equity raisings to fund them.*
Advised ASX listed Billabong International Limited on the $60 million sale of its Tigerlily fashion business to private equity firm Crescent Capital.*
Advised Emeco Holdings in connection with the $69.8 million acquisition of Force Equipment and $80 million acquisition of Matilda Equipment Holdings and associated equity raisings to fund them.*
Advised NSW Government on the sale to the private sector of some of its electricity assets and businesses.*
Advised NSW Government on Crown Sydney's resort and gaming facility at Barangaroo.*
Advised Sims Group on its US$1.7 billion merger with Metal Management, Inc. and the subsequent listing of Sims ADS on NYSE.*
Advised KKR on its investment in the $4 billion media joint venture with Seven Networks Limited and its sale to Western Australian Newspapers Limited.*
Acted for HT&E Limited on the demerger of its NZ media business, NZME, and its listing on ASX and NZX.*
Advised Duke Energy in the disposal of its $1.7 billion portfolio of gas pipeline and electricity generation assets in Australia and New Zealand to Alinta Limited.*
Advised TPG on the $3 billion take private of Alinta by means of a court sanctioned creditors scheme approved in March 2011 and complementary schemes at the listed entity level.*
Advised Sims Group on its $650 million acquisition of Sims Hugo Neu Company LLC and its restructure by scheme of arrangement.*
Advised MIA Group in connection with its merger by scheme of arrangement with DCA Group Limited with a deal value of $700 million.*
*Matter handled prior to joining Hogan Lovells.
Latest thinking and events
Foreign Investment in Australia: what you need to know
Press Releases
Hogan Lovells advises Aware Super on their A$3.5bn consortium bid with MIRA for ASX Listed Vocus Group Limited
31 March 2021
Webinar
Sports and esports - the same but different?!
Session 1: 24 February 2021, 3:00 PM EST – 4:00 PM EST | Session 2: 02 March 2021, 5:00 PM – 6:00 PM HKT
News
The rise of FDI regimes and their impact on M&A transactions
22 January 2021
Analysis
Major reforms to Australia’s foreign investment framework to commence on 1 January 2021
Registered Content
24 December 2020
Press Releases
Hogan Lovells advises Novartis in respiratory cell therapy licensing deal with Mesoblast
23 November 2020
